Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells
Citations Over TimeTop 1% of 2016 papers
Abstract
Cancer therapy has traditionally focused on eliminating fast-growing populations of cells. Yet, an increasing body of evidence suggests that small subpopulations of cancer cells can evade strong selective drug pressure by entering a 'persister' state of negligible growth. This drug-tolerant state has been hypothesized to be part of an initial strategy towards eventual acquisition of bona fide drug-resistance mechanisms. However, the diversity of drug-resistance mechanisms that can expand from a persister bottleneck is unknown. Here we compare persister-derived, erlotinib-resistant colonies that arose from a single, EGFR-addicted lung cancer cell. We find, using a combination of large-scale drug screening and whole-exome sequencing, that our erlotinib-resistant colonies acquired diverse resistance mechanisms, including the most commonly observed clinical resistance mechanisms. Thus, the drug-tolerant persister state does not limit--and may even provide a latent reservoir of cells for--the emergence of heterogeneous drug-resistance mechanisms.
Related Papers
- → Persisters and beyond: Mechanisms of phenotypic drug resistance and drug tolerance in bacteria(2013)211 cited
- → Drug resistance mechanisms of cancer stem-like cells and their therapeutic potential as drug targets(2019)24 cited
- → Antagonistic drug combinations that select against drug resistance: From bacteria to cancer(2007)16 cited
- → Strategies to Estimate And Improve Drug Tolerance in Anti-Drug Antibody Assays(2012)9 cited
- → Drug tolerance, persister cells and drug discovery.(2012)1 cited